Mumbai, Feb. 12 -- Early-stage healthcare-focused venture capital firm W Health Ventures is looking for bolder bets with its second fund, building companies from the ground up in areas like oncology, ... Read More
New Delhi, Feb. 11 -- Contract drug manufacturer OneSource Specialty Pharma received approval for its generic version of Ozempic in Saudi Arabia, clearing the path for selling the type-2 diabetes and ... Read More
New Delhi, Feb. 10 -- Apollo Hospitals on Tuesday beat Street estimates in the quarter ended December, led by strong demand for specialty care and double-digit growth across businesses. The hospital c... Read More
New Delhi, Feb. 10 -- French drug innovator Servier is partnering with domestic players to develop, manufacture and export formulations for the global market, highlighting India's growing role in glob... Read More
New Delhi, Feb. 4 -- Emcure Pharmaceuticals is tapping influencers and celebrities on social media, in addition to raising awareness among doctors, for its semaglutide brand, Poviztra, as it seeks to ... Read More
MUMBAI, Feb. 3 -- India's push to become a global hub for drug development faces a basic constraint: the country does not have enough standardized, trial-ready hospitals and clinics to scale up to mee... Read More
New Delhi, Feb. 3 -- Mankind Pharma's net profit climbed 9.5% in the third quarter, missing estimates, as revenue increased, driven by domestic growth and consolidation of Bharat Serums and Vaccines L... Read More
New Delhi, Jan. 31 -- The Mumbai-based drugmaker said its total sales rose 15.1% year-on-year to Rs.15,469 crore. Total revenue from operations rose 13.4% YoY to Rs.15,520.5 crore, the company said in... Read More
New Delhi, Jan. 30 -- Sun Pharma, India's largest drugmaker, is set to post its results for the third quarter of the fiscal year on Saturday. While brokerages anticipate steady domestic growth and mar... Read More
New Delhi, Jan. 29 -- Piramal Pharma Ltd is starting to see early signs of a recovery in its contract manufacturing business, with order inflows picking up on the back of improved biopharma funding an... Read More